Abstracts Archive - Page 604 of 2607 - ACR Meeting Abstracts

Abstract Number: 1822 • ACR Convergence 2022
A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia
Marc Gurwith¹, Deon Smith², Paul Bird³, Jessica Leung⁴, Mark Bloch⁵, Joshua Kim⁶, Rahul Mohan⁷, Anthony Houston⁸, Oscar Cumming⁹, Ann Madrid¹⁰, Ullrich Schwertschlag¹¹, Jerry Liu¹², Roy Wu¹³, Jason Xu¹⁴, Adam Jin¹⁴ and William Dongfang Shi¹⁵, ¹Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Los Altos Hills, CA, ²Emeritus Research, Melbourne, Australia, ³Emeritus Research Sydney, Sydney, Australia, ⁴Austin Health, Preston, Victoria, Australia, ⁵Holdsworth House Medical Practice, Darlinghurst, Australia, ⁶Paratus Clinical Pty Ltd., New South Wales, Australia, ⁷Paratus Clinical Pty Ltd, Western Sydney, Australia, ⁸Peninsula Private Hospital, Kippa-Ring, Australia, ⁹Novatrials, Kotara, Australia, ¹⁰Novotech Australia, Sydney, Australia, ¹¹Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Palo Alto, ¹²Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., San Diego, ¹³Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., San Francisco, ¹⁴Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Suzhou, China, ¹⁵Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Fremont
Background/Purpose: ABP-671, a novel selective and potent URAT1 inhibitor reduces reabsorption of uric acid (UA) at the renal proximal tubule, and significantly decreases serum uric…
Abstract Number: 1823 • ACR Convergence 2022
Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
Tamer A Gheita¹, Ahmed M Elsaman², Aly Bakhiet³, Mohamed Bakrey Mahmoud⁴, Faten Ismail⁵, Hanan El Saadany⁶, Rawhya R ElShereef⁵, Eman F Mohamed⁷, Mervat I Abd Elazeem⁸, Ayman Eid⁸, Fatma Ali⁵, Mona Hamdy⁵, Reem El Mallah⁹, Reem HA Mohammed¹, Samar Tharwat¹⁰, Rania M Gamal¹¹, Samar Fawzy¹, Soha Senara¹², Hanan M Fathi¹², Adham Aboul Fotouh¹³ and Nevin Hammam¹⁴, ¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Higher Institute for Computer Science and Information Systems, 6th of October City, Assiut, Egypt, ⁴Higher Institute for Computer Science and Information Systems, 6th of October City, Cairo, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ⁶Rheumatology Department, Tanta University, Gharbia, Egypt, ⁷Internal Medicine Department, Rheumatology Unit, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, ⁸Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ¹⁰Internal Medicine, Rheumatology Unit, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, ¹²Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, ¹³Egyptian School for Musculoskeletal Ultrasonography (EgySMUS); Egyptian Society of Musculoskeletal and Neuromuscular Sonography (ESMNS), Cairo, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA
Background/Purpose: Gout comprises a heterogeneous group of disorders characterized by inflammatory arthritis associated with comorbidities leading to impaired quality of life, and an extensive burden…
Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Mary Grace Whelan¹, Keigo Hayashi² and Sara Tedeschi¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…
Abstract Number: 1821 • ACR Convergence 2022
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Jasvinder singh¹, Timothy Bergquist², Vithal Madhira³ and Alfred Anzalone⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sage Bionetworks, Seattle, WA, ³Palila Software, L.L.C., Reno, NV, ⁴University of Nebraska Medical Center, Ohama, NE
Background/Purpose: To examine whether the use of colchicine and other gout medications is associated with the risk of COVID-19 infection, hospitalization, and subsequent outcomes in…
Abstract Number: 1834 • ACR Convergence 2022
Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study
Ibrahim Durucan¹, Ali Yagiz Ayla², Helin Idil Besiroglu¹, Arif Alkan¹, Oguzhan Selvi¹, Huri Ozdogan¹ and Serdal Ugurlu², ¹Istanbul University-Cerrahpaşa Medical Faculty, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa, Istanbul, Turkey
Background/Purpose: Recurrent fever and serositis are the hallmarks of Familial Mediterranean fever (FMF). Colchicine is known for yielding high success in disease control by obviating…
Abstract Number: 1828 • ACR Convergence 2022
Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
Rachael Flood¹, Colm Kirby¹, yousef Alammari², David Kane¹ and Ronan Mullan¹, ¹Tallaght University Hospital, Dublin, Ireland, ²Imam Mohammad Ibn Saud Islamic University, RIYADH, Ar Riyad, Saudi Arabia
Background/Purpose: Emerging evidence that joints of asymptomatic hyperuricaemic individuals contain monosodium urate (MSU) deposits and that alternative presentations of foot pain occur in hyperuricaemia suggests…
Abstract Number: 1830 • ACR Convergence 2022
Characteristics of Arthritis in Familial Mediterranean Fever Patients
Ali Yagiz Ayla¹, Selcan Yenigun², sura nur baspinar³, Mebrure Burcak Yuzbasioglu², Arif Alkan³, Ibrahim Durucan³, mert kirman³, baran can polat³, sercan ergun³, Serdal Ugurlu¹ and Huri Ozdogan³, ¹Istanbul University-Cerrahpaşa, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa Medical Faculty Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpaşa Medical Faculty, Istanbul, Turkey
Background/Purpose: Arthritis is one of the most common manifestations in an FMF attack. It is usually in the form of acute mono- or oligoarthritis of…
Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Sandra Hermann¹, Andriko Palmowski¹, Bukrhard Muche², Kay-Geert Hermann³, Edgar Wiebe¹ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…
Abstract Number: 1837 • ACR Convergence 2022
Eales Disease and Vogt-Koyanagi-Harada Syndrome: Not Everything Is Anterior Uveitis in Rheumatology
Sonia Pastor Navarro¹, Olga Compán Fernández¹, Marta Ibáñez Martínez¹, Belén Miguel Ibáñez¹, Mireia Molina Pérez², Ángel Beltrán Mazo², Olga Martínez González¹, Carlos Montilla Morales¹, Ana Isabel Turrión Nieves¹, Susana Gómez Castro³ and Cristina Hidalgo Calleja¹, ¹Hospital Universitario de Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³Hospital Universitario Salamanca, Salamanca, Spain
Background/Purpose: Ocular inflammatory involvement for being closely related to systemic autoimmune diseases is monitored and treated in our rheumatology visits. The most frequently studied by…
Abstract Number: 1839 • ACR Convergence 2022
Appendicitis Still a Challenge for FMF Patients?
Şura Nur Başpınar¹, Arif Alkan², Mebrure Burcak Yuzbasioglu³, Selcan Yenigun³, Ali Yagiz Ayla⁴, Ibrahim Durucan², Mert Candan², Ali Karabiçek², Çağrı Belli², Tuğba Bayraktar², Helin Idil Besiroglu², Huri Ozdogan⁵ and Serdal Ugurlu⁴, ¹İstanbul University-Cerrahpaşa Medical Faculty Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa Medical Faculty, Istanbul, Turkey, ³Istanbul University-Cerrahpaşa Medical Faculty Department of Internal Medicine, Istanbul, Turkey, ⁴Istanbul University-Cerrahpaşa, Istanbul, Turkey, ⁵Istanbul University-Cerrahpaşa Medical Faculty Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disease that is characterized by recurrent episodes of polyserositis. Episodes typically consist of fever, peritonitis, and…
Abstract Number: 1836 • ACR Convergence 2022
Schizophrenia and Its Relationship with Autoimmunity: A Nationwide Analysis
Faria Sami¹, Dennis Kumi¹, Sumbul Liaqat² and Hania Sami³, ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Shalamar Medical and Dental College, Chicago, IL
Background/Purpose: It has been hypothesized that autoimmunity may play a role in the pathophysiology of schizophrenia (SCZ). Several autoimmune disorders (AID) have also been noted…
Abstract Number: 1838 • ACR Convergence 2022
Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States
Arielle Bensimon¹, Kristina Chen², Ahmed Noman¹, Erica Yim¹, Jason Xenakis³ and Rohit Aggarwal⁴, ¹Analysis Group, Inc., Boston, MA, ²Pfizer Inc., Cambridge, MA, ³Pfizer Inc., New York, NY, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease characterized by muscle weakness, skin rashes, and elevated risk of associated conditions such as interstitial…
Abstract Number: 1330 • ACR Convergence 2022
Impact of COVID-19 Severity on Physical Function, Mobility, Falls and Fractures Among Older Patients After Hospitalization: A Longitudinal Study
Clara Wong¹, Diego Cabrera², Mary Geda³, Andrew Cohen³, Lauren Ferrante³, Alexandra Hajduk³ and Evelyn Hsieh², ¹Yale School of Public Health, New Haven, CT, ²Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, ³Yale School of Medicine, New Haven, CT
Background/Purpose: No longitudinal studies have examined the impact of COVID-19 or COVID-19 severity on physical function and disability outcomes among older adults. Multiple factors, including…
Abstract Number: 1780 • ACR Convergence 2022
Improved Overall Survival in Patients with Lung Cancer and Autoimmune Rheumatic Diseases
Paola Ghanem¹, Joseph C. Murray¹, Christopher Mecoli², Ami Shah³, Benjamin Levy¹, Kristen A. Marrone¹, David Ettinger¹, Valsamo Anagnostou¹, Vincent K. Lam¹, Julie R. Brahmer¹ and Laura C. Cappelli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Lung cancer remains the leading cause of cancer-related death. Concomitant autoimmune diseases (AD) can add morbidity and complicate treatment decisions. We evaluated the tumor…
Abstract Number: 1729 • ACR Convergence 2022
SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis
Mégane Lacaud¹, Houda-Ghozlane Bouzidi¹, Magali Breckler², Delphine Lemeiter², Johanna Sigaux³, Luca Semerano⁴, Marie-Christophe Boissier⁵, Natacha Bessis⁶ and Jerome Biton⁷, ¹Sorbonne Paris Nord University, Inserm U1125, Bobigny, France, ²Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ³Avicenne Hospital, Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ⁴Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France, ⁵INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ⁶INSERM 1125 and University Sorbonne Paris Nord, Bobigny, France, ⁷INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France
Background/Purpose: CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). Usually, chronic stimulation of T…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].